Bristol Myers scores FDA priority review in high-stakes expansion bid for CAR-T drug Breyanzi

The FDA has accepted Bristol Myers Squibb's application for Breyanzi as a second-line treatment for relapsed or refractory large B-cell lymphoma. The regulator has assigned it priority review with a decision deadline of June 24.

Related Keywords

United States ,American ,Roche Rituxan ,Giovanni Caforio ,Chris Boerner ,Ann Kerber ,American Society Of Hematology ,Bristol Myers Squibb ,American Society ,Breyanzi ,Abecma ,Rituxan ,Revlimid ,Car T ,Blood Cancer ,Lymphoma , ,